Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors by Kolberg, Matthias et al.
Drug sensitivity and resistance testing identifies PLK1
inhibitors and gemcitabine as potent drugs for malignant
peripheral nerve sheath tumors
Matthias Kolberg1,2,† , Jarle Bruun1,2,†, Astrid Murum€agi3, John P. Mpindi3, Christian H.
Bergsland1,2, Maren Høland1,2, Ina A. Eilertsen1,2, Stine A. Danielsen1,2, Olli Kallioniemi3,4,5 and
Ragnhild A. Lothe1,2
1 Department of Molecular Oncology, Institute for Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Norway
2 Centre for Cancer Biomedicine, University of Oslo, Norway
3 Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Finland
4 Science for Life Laboratory, Solna, Sweden
5 Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden
Keywords
drug screen; MPNST; pharmacology;
Schwann cell
Correspondence
R. A. Lothe, Department of Molecular
Oncology, Institute for Cancer Research,
The Norwegian Radium Hospital, Oslo
University Hospital, PO Box 4950 Nydalen,
NO-0424 Oslo, Norway
Fax: +47 2278 1745
Tel: +47 2278 1728
E-mail: rlothe@rr-research.no
†Shared first authorship
(Received 27 February 2017, revised 24
April 2017, accepted 16 May 2017, available
online 5 July 2017)
doi:10.1002/1878-0261.12086
Patients with malignant peripheral nerve sheath tumor (MPNST), a
rare soft tissue cancer associated with loss of the tumor suppressor
neurofibromin (NF1), have poor prognosis and typically respond
poorly to adjuvant therapy. We evaluated the effect of 299 clinical and
investigational compounds on seven MPNST cell lines, two primary
cultures of human Schwann cells, and five normal bone marrow aspi-
rates, to identify potent drugs for MPNST treatment with few side
effects. Top hits included Polo-like kinase 1 (PLK1) inhibitors (volaser-
tib and BI2536) and the fluoronucleoside gemcitabine, which were vali-
dated in orthogonal assays measuring viability, cytotoxicity, and
apoptosis. DNA copy number, gene expression, and protein expression
were determined for the cell lines to assess pharmacogenomic relation-
ships. MPNST cells were more sensitive to BI2536 and gemcitabine
compared to a reference set of 94 cancer cell lines. PLK1, RRM1, and
RRM2 mRNA levels were increased in MPNST compared to benign
neurofibroma tissue, and the protein level of PLK1 was increased in
the MPNST cell lines compared to normal Schwann cells, indicating an
increased dependence on these drug targets in malignant cells. Further-
more, we observed an association between increased mRNA expression
of PLK1, RRM1, and RRM2 in patient samples and worse disease
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outcome, suggesting a selective benefit from inhibition of these genes in
the most aggressive tumors.
1. Introduction
Malignant peripheral nerve sheath tumors (MPNST)
are rare and aggressive soft tissue cancers that arise
from cells of neuroectodermal origin in the peripheral
nervous system. MPNST often strikes young adults
and adolescents, and nearly half of all cases are associ-
ated with the genetic syndrome neurofibromatosis type
1 (NF1, MIM 162200). The median age for the NF1-
associated cases is around 25 years, while the sporadic
cases have a median in the forties (Kolberg et al.,
2013). The 5-year overall survival rate for MPNST is
less than 50%, and in recent years, the prognosis has
been similar for NF1 and non-NF1 patients (Kolberg
et al., 2013). There are currently no consensus guideli-
nes for adjuvant treatment with curative intent for
MPNST (Bradford and Kim, 2015), and there is a crit-
ical need for new treatment options.
Management of MPNST is currently based on gen-
eral soft tissue sarcoma guidelines and involves surgery
and occasionally chemo- and radiotherapy (ESMO,
2014). Some relapse control has been reported follow-
ing radiotherapy (Yang et al., 1998); however, radia-
tion itself can be a significant risk factor, especially for
patients with NF1 (Sharif et al., 2006). The rareness of
MPNST and other soft tissue cancers precludes robust
clinical trials, and the trials will often include several
sarcoma entities with different genetic composition,
tumor biology, and hence different drug response.
There are 62 interventional trials listed in the US-
based National Institutes of Health (NIH) database
that are eligible for patients with MPNST, and 16 of
these are currently open or are recruiting patients
(Table S1). However, most trials include several differ-
ent sarcomas, often leaving the numbers of MPNSTs
too low, lacking statistical power to conclusively docu-
ment any benefit for these patients. Only a handful of
trials have focused specifically on MPNST with focus
on compounds that target the biological processes
involved in MPNST development (Table 1). So far,
however, none of these trials have compelled changes
in the management of this malignancy. Notably, the
SARC006 trial, which tested the effect of the TOP2A
inhibitors doxorubicin and etoposide in combination
with ifosfamide, reported an overall response rate of
33% in the sporadic and 17% in NF1-associated
MPNST, respectively, although both were below the
set target of 40% (Widemann et al., 2013). The
TOP2A gene has previously been identified as ampli-
fied and upregulated in a large subset of MPNST
patient samples (Skotheim et al., 2003), which could
explain the positive effect of TOP2A inhibition in
these patients.
Malignant peripheral nerve sheath tumors are highly
complex malignancies with multiple copy number
alterations (Brekke et al., 2010; Lothe et al., 1996;
Mertens et al., 2000) including alterations in several
clinically relevant target genes at chromosome arm 17q
(Kolberg et al., 2015; Skotheim et al., 2003; Storlazzi
et al., 2006). Inactivating mutations in the NF1 tumor
suppressor gene are found in both NF1-associated and
sporadic MPNST (Bottillo et al., 2009; Upadhyaya
et al., 2008). Loss of NF1 activity leads to activation
of RAS and consequently contributes to the PI3K/
AKT/mTOR and RAF/MEK/ERK signaling in
MPNST (Agesen et al., 2005; Berner et al., 1999;
Brems et al., 2009; Danielsen et al., 2015; Endo et al.,
2013; Nielsen et al., 1999). Components of this net-
work have been investigated as potential therapeutic
targets (Fig. S1). In preclinical MPNST models, some
drugs targeting these pathways have shown encourag-
ing results, including the mTOR inhibitors everolimus
and AZD8055 (De Raedt et al., 2011; Endo et al.,
2013; Varin et al., 2016), and the multikinase Raf inhi-
bitor sorafenib (Ambrosini et al., 2008; Castellsague
et al., 2015), as well as a selection of other drugs that
inhibit pathways associated with NF1, such as gemc-
itabine (Schoeler et al., 2007), erlotinib (Mahller et al.,
2007), imatinib (Aoki et al., 2007; Patwardhan et al.,
2014), pexidartinib (Patwardhan et al., 2014), and
sunitinib (Zietsch et al., 2010). However, clinical trials
have not confirmed any therapeutic benefit for the lim-
ited number of drug candidates identified by a knowl-
edge-based approach (Table 1). Of note, a recent study
suggests the effect of MEK inhibitor selumetinib
against inoperable plexiform neurofibromas in children
with NF1 (Dombi et al., 2016).
As a complement to the knowledge-based drug dis-
covery approach, we here present a comprehensive
high-throughput approach to identify new therapeutic
opportunities for MPNST among a large panel of clin-
ical and investigational drugs. We identify and rank
the compounds with the highest effect and specificity
for MPNST cells by pharmacological analysis of seven
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MPNST cell lines using two normal Schwann cell cul-
tures and bone marrow aspirates from healthy donors
as controls. Candidate drugs showing the highest selec-
tivity were subjected to validation in independent
experiments.
2. Material and Methods
2.1. Cell lines, primary cultures, and patient
material
The original drug testing assay included two primary
cultures of human Schwann cells (HSC) termed HSC1
and HSC2 that were isolated from human spinal
nerves (ScienCell, Carlsbad, CA, USA) and four
MPNST cell lines, STS26T (Dahlberg et al., 1993) and
ST8814 (Reynolds et al., 1992) (kindly provided by
Nancy Ratner, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH, USA), and S462 (Frahm
et al., 2004) and S1507-2 (Spyra et al., 2011) (kindly
provided by Lan Kluwe, University Medical Center
Hamburg-Eppendorf, Germany). Later, the three
MPNST cell lines HS-PSS, HS-Sch-2 (Sonobe et al.,
2000), and YST-1 (Nagashima et al., 1990) (Riken
BioResource Center, Ibaraki, Japan) were assayed with
an extended and updated drug library (see below).
Table 1. Clinical trials with main focus on MPNSTa.
Trial ID Intervention Drug class Phase Patient enrollment Status and results
NCT01661283
(SARC016)







Clinical benefit rate (CBR):
12% (3 of 25)
(Widemann et al., 2016)
NCT00464620
(SARC009)
Dasatinib Kinase inhibitor (KIT Src) II 14 MPNST Active, not recruiting
All progressed within












Overall response rate 17% in
NF1, 33% in sporadic
(Widemann et al., 2013)




One stable disease; 19 no
response. Median
progression-free survival:
2 months. Median overall
survival: 4 months
(Albritton et al., 2006)
NCT02008877
(SARC023)
Ganetespib, sirolimus HSP inhibitor and
mTOR inhibitor
I/II 38 MPNST Active, not recruiting






I/II 5 sarcoma Terminated
NCT00427583 Imatinib mesylate Kinase inhibitor II/III 7 MPNST Terminated
All were taken off study;
5 due to progressive disease,
one due to toxicity, and one
withdrawal (Chugh et al., 2009)
NCT02691026 Pembrolizumab Cell surface receptor
antibody





I/II 49 MPNST Recruiting




II 12 MPNST evaluated Completed.
All progressed within 12 months.
Mean PFS: 1.7 months.
Two patients with MPNST
had regression or cystification
of metastatic disease without a
RECIST response
(Maki et al., 2009)
aData from clinicaltrials.gov.
1158 Molecular Oncology 11 (2017) 1156–1171 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
MPNST drug sensitivity and resistance testing M. Kolberg et al.
STS26T and YST1 were derived from non-NF1
patients and have been reported to express wild-type
NF1 (Miller et al., 2006; Nagashima et al., 1990), and
the remaining cell lines are derived from NF1 patients
and do not express NF1.
All cancer cell lines were maintained in DMEM-F12
medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 unitsmL1 penicillin, and
100 lgmL1 streptomycin (Gibco, Thermo Fisher Sci-
entific, Waltham, MA, USA). The HSC were main-
tained in Schwann cell medium (SCM, Cat. no. 1701,
ScienCell) supplemented with Schwann cell growth
supplement (SCGS, Cat. no. 1752, ScienCell) accord-
ing to the suppliers’ recommendations.
The identity of the cell lines was validated by geno-
typing of the isolated DNA (Table S2, Appendix S1)
according to the protocol of the AmpFLSTR Identifiler
PCR Amplification Kit (Life Technologies by Thermo
Fisher Scientific). For the cell lines YST-1, HS-PSS, HS-
Sch-2, identical STR profiles were provided by Riken
(also available at www.expasy.org/cellosaurus), and for
STS26T and ST8814, identical STR profiles were
obtained by N. Ratner (personal communication). All
the cell lines were tested and found negative for myco-
plasma contamination using the MycoAlert detection
kit (Lonza Ltd, Basel, Switzerland).
Fresh-frozen tumor material was available from 30
MPNSTs (17 NF1-associated and 13 non-NF1 cases)
and eight benign neurofibromas (seven dermal and one
plexiform) from Oslo University Hospital, Oslo, Nor-
way, and Skane University Hospital, Lund Sweden, as
previously described (Kolberg et al., 2015). Briefly,
DNA and RNA were extracted from tissue sections
consisting of >90% representative tumor tissue as iden-
tified by a reference sarcoma pathologist. Informed
consent was obtained from all living patients, and the
study was approved by the South-Eastern Norway
Regional Health Authority and the Regional Ethics
Committee at Lund University according to national
legislation. Bone marrow aspirates were collected from
five healthy donors after informed consent using
approved study protocols (Helsinki Ethical Committee
239/13/03/00/2010 and 303/13/03/01/2011).
2.2. Drug sensitivity and resistance testing and
data analysis
Drug sensitivity and resistance testing (DSRT) was
performed as described earlier (Pemovska et al., 2013)
on all seven MPNST cell lines and two normal HSC
cultures. The initial drug library contained 309 com-
pounds, while three MPNST cell lines were screened
with 527 compounds (303 overlapping). Reference
DSRT data were also available for 299 overlapping
drugs for five primary cultures of adult human bone
marrow cells derived from healthy donors, and from
a reference collection of cell lines from different can-
cer types, including colorectal (n = 36), ovarian
(n = 30), and acute myeloid leukemia (n = 28)
(Mpindi et al., 2016). Briefly, the compounds were
dissolved in 100% dimethyl sulfoxide (DMSO) or
water (Table S3) and dispensed on tissue culture-
treated 384-well plates (Cat. No. 3707, Corning,
Tewksbury, MA, USA) using an acoustic liquid han-
dling instrument, Echo 550 (Labcyte Inc., Sunnyvale,
CA, USA). The compounds were plated in five con-
centrations using 10-fold dilutions covering a 10 000-
fold concentration range (e.g., 1–10 000 nmolL1).
The preprinted plates were kept in pressurized Stor-
agePods (Roylan Developments Ltd., Fetcham, UK)
under inert nitrogen gas until needed. Five microlitre
of CellTox-Green (CTX) Cytotoxicity Assay Reagent
(Promega, Fitchburg, WI, USA), 1 : 200 dilution in
growth media, was added to each 384-well plate prior
to seeding of cells to achieve a final concentration of
1 : 1000. The CTX assay is based on quantification of
fluorescence-labeled DNA released from disrupted
cells. Plates were subsequently centrifuged briefly and
put on an orbital shaker for 10 min. Twenty micro-
liters of single-cell suspension (750–1000 cells) was
transferred to each well using a Multidrop Combi
Reagent Dispenser (Thermo Fisher Scientific). Prolif-
eration rates and growth patterns of the cell lines
were evaluated prior to the experiments in order to
determine the optimal cell seeding density to assure
logarithmic growth throughout the 72-h incubation
period. The plates were incubated in a humidified
environment at 37 °C and 5% CO2, and after 72 h,
cell cytotoxicity and cell viability (assessed using Cell-
Titer-Glo (CTG) Luminescent Cell Viability Assay,
Promega) were measured according to the manufac-
turer’s instructions with a PHERAstar FS microplate
reader (BMG Labtech GmbH, Ortenberg, Germany).
The CTG assay generates luminescence proportional
to the amount of ATP that is extracted from living
cells in the culture. The data were normalized to neg-
ative control (0.1% DMSO) and positive control wells
(containing 100 lM benzethonium chloride, effectively
killing all cells). Quality control (QC) metrics, Z0, and
strictly standardized mean difference (SSMD, i.e., the
effect size) for each plate were calculated as described
(Mpindi et al., 2015; Yadav et al., 2014). Drug sensi-
tivity scores (DSS) were calculated for both the CTG
assay (DSSCTG) and the CTX assay (DSSCTX) by fit-
ting of the dose–response curves on the basis of a
four-parameter logistic fit function defined by the top
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and bottom asymptote, the slope, and the inflection
point (IC50). In the curve fitting, the bottom asymp-
tote of the curve was fixed to 0% inhibition (=100%
viability), whereas the top asymptote was allowed to
float above 10% inhibition (i.e., drugs causing < 10%
inhibition were considered inactive, DSS0), and the
slope was allowed to float between 0 and 2.5 (Mpindi
et al., 2015; Yadav et al., 2014). For validation, the
orthogonal ApoToxGlo Triplex assay (Promega) was
performed according to the manufacturer’s instruc-
tions, in parallel with the CTG assay (using 15 dilu-
tions from 1 000 nM to 0.0625 nM for each drug). The
Triplex assay allows for luminescence measurements
of caspase 3/7 activity as a measure of apoptosis
levels in addition to viability and cytotoxicity in
response to drug treatment. Cells treated with 0.1%
DMSO were used as negative controls, 10 lM stau-
rosporin was used as positive control for apoptosis,
while 100 lM benzethonium chloride was used as pos-
itive control for viability and cytotoxicity.
The average quality control value (Z0) for all cell lines
in the viability assay was 0.72  0.04 and average
SSMD was 14.1  2.4 for each drug plate (Table S4A).
The two cell lines S462 and S1507-2 were re-tested for
technical validation demonstrating high reproducibility
of the CTG data [Pearson’s correlation r = 0.990 and
0.975, respectively (Fig. S2A and S2B)]. For the two
independent normal HSC cultures, the Pearson’s corre-
lation was r = 0.982 (Fig. S2C). Overall, there was also
a strong correlation in drug response patterns between
the MPNST cell lines and the HSC primary cultures
(Pearson’s correlation r = 0.924) and to a lesser extent
between MPNST and bone marrow (Pearson’s correla-
tion r = 0.752) (Fig. S2D). For the cytotoxicity assay,
three cell lines (S462, YST-1, and HS-Sch-2) failed the
quality control. The remaining cell lines had an average
Z0 of 0.58  0.13 and an average SSMD of 10.5  3.0
(Table S4B).
2.3. Reverse-phase protein array analyses
Expression of 297 cancer-related proteins and phos-
phoproteins was evaluated by reverse-phase protein
array analyses (RPPA) at the MD Anderson RPPA
core facility (Houston, TX, USA) in the four MPNST
cell lines, S1507-2, S462, ST8814, and STS26T, and
normal HSC1 according to the published protocol
(Tibes et al., 2006). Later, the MPNST cell lines YST-
1, HS-PSS, and HS-Sch-2, as well as a replicate of the
HSC1, were submitted to the same analysis using an
updated RPPA version including 306 antibodies, of
which 271 were overlapping with the initial 297 anti-
bodies.
2.4. Gene expression analysis
The genome-wide gene expression levels of the seven
MPNST cell lines, HS-PSS, HS-Sch-2, S1507-2, S462,
ST8814, STS26T, and YST-1, as well as the normal
HSC1, were assessed by synthesis of cDNA from iso-
lated RNA and subsequent hybridization to the Gene-
Chip Human Transcriptome Array 2.0 according to
the supplier’s protocol (Affymetrix, Thermo Fisher
Scientific Inc.) (see Appendix S1).
2.5. DNA copy number analyses
DNA from four MPNST cell lines, S1507-2, S462, ST8814,
and STS26T, were individually processed and hybridized
on Genome-Wide Human SNP Array 6.0 from Affymetrix
(Thermo Fisher Scientific Inc.) as described in the Affyme-
trix Cytogenetics Copy Number Assay User Guide (P/N
702607 Rev. 2) (see Appendix S1).
2.6. Mutation analyses
The genes TP53 (exon 2–11) and BRAF (exon 15) were
sequenced using DNA extracts of the four MPNST cell
lines S1507-2, S462, ST8814, and STS26T by Sanger
sequencing using in-laboratory-established protocols (Ahl-
quist et al., 2008; Berg et al., 2010) (see Appendix S1).
2.7. Statistical analyses
Association between gene expression and disease-speci-
fic survival was analyzed using Cox proportional haz-
ards regression modeling with Wald test to provide
univariate hazard ratios (HR) and confidence intervals
(CI) and visualized by Kaplan–Meier plots. Compar-
ison of gene expression differences between MPNST
cell lines and other cell lines, and between MPNST
patient samples and neurofibromas, was assessed by
two-tailed Student’s t-test for independent samples,
and correlations between drug screen data from
repeated or separate runs were assessed by Pearson’s
test. Spearman’s correlation was used to compare IC50
from different screening platforms to reduce influence
of outliers. All statistical analyses were performed
using the SPSS 21 software (IBM Corporation,
Armonk, NY, USA).
3. Results
3.1. Identification of MPNST-specific drugs
Four MPNST cell lines S1507-2, S462, ST8814, and
STS26T and two HSC primary cultures were subjected
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to high-throughput DSRT with 309 emerging and clin-
ical oncology compounds. Three additional MPNST
cell lines HS-PSS, HS-Sch-2, and YST-1 were screened
using an updated compound library of 527 compounds
(with 303 compounds overlapping between both
libraries). Data for 299 of these drugs were also avail-
able from normal bone marrow aspirates from healthy
donors. As drug sensitivity readout, we used two
chemically different assays measuring cell viability
(CTG; Fig. 1A; Table S5) and cytotoxicity (CTX;
Fig. S3, Table S6).
Twenty of the tested compounds are used in the
clinic to treat MPNST (ESMO, 2014), or have been
tested in recent clinical trials including patients with
MPNST (MPNST trials: Table 1; sarcoma trials:
Table S1). Twelve of these showed strong to moderate
response in MPNST cells (DSSCTG > 5) in our assay,
and they also showed differential response in MPNST
cells as compared to bone marrow cells (missing data
for ganetespib and carboplatin in bone marrow)
(Fig. 1B). Only three, docetaxel, vincristine, and
BI2536, showed selectively higher response in MPNST
cells as compared to HSC (Fig. 1B, Table S5). Strik-
ingly, both mTOR inhibitors temsirolimus and everoli-
mus appear to be more effective in normal HSC than
in MPNST cells, while sirolimus did not inhibit any of
the cells in our assay at the concentrations used.
To systematically identify the most potent drugs, the
DSSCTG values were filtered according to MPNST
specificity and off-target toxicity (Fig. 2). Of the 299
drugs tested in all cell types, including bone marrow,
111 had DSSCTG ≥ 10 in at least one MPNST cell line.
Eighty-one of these were well, or moderately, tolerated
in bone marrow cells (DSSCTG < 10 in bone marrow),
and of these, 49 drugs showed differential sensitivity in
MPNST cells with five or more DSSCTG units higher
in MPNST cells as compared to normal bone marrow.
Nine of these drugs also showed higher selectivity for
MPNST cells as compared to HSC (DDSSCTG(MPNST
vs. HSC) ≥ 5). These included the polo-like kinase 1
(PLK1) inhibitor BI2536, three tubulin/kinesin inhibi-
tors (vinorelbine, vincristine, and SB 743921), two
nucleoside analogs (floxuridine and thioguanine), two
folate analogs (methotrexate and pemetrexed), as well
as one proteasome-ubiquitin inhibitor [NEDD8-acti-
vating enzyme (NAE) inhibitor pevonedistat]. Four of
these nine compounds were selected for validation:
BI2536 was selected as a targeted kinase inhibitor,
floxuridine was selected due to its association with thy-
midine kinase 1 (TK1), previously identified as a prog-
nostic biomarker (Kolberg et al., 2015), while
methotrexate and pemetrexed were selected for their
differential response in MPNST cell lines. In addition,
a second PLK1 inhibitor, volasertib, and a second flu-
oronucleoside, gemcitabine, were included from the list
of 49 compounds with selectivity toward MPNST cells
over bone marrow cells. Three of these six compounds,
BI2536, volasertib, and gemcitabine, also showed a
strong cytotoxic effect (DSSCTX > 10) in the MPNST
cells, while methotrexate, pemetrexed, and floxuridine
showed limited or no cytotoxicity in the CTX assay
(Table S6).
The validation experiments for BI2536, volasertib,
gemcitabine, methotrexate, pemetrexed, and flox-
uridine were performed using orthogonal assays in
four MPNST cell lines (Fig. S4). A good correlation
between the initial screen and the validations was
observed for the two PLK1 inhibitors, BI2536 and
volasertib, as well as for gemcitabine (Fig. 3A). How-
ever, the high drug responses for methotrexate, peme-
trexed, and floxuridine observed in the initial DSRT
were not confirmed (Fig. S4). Interestingly, the
DSSCTG values of BI2536 and volasertib appear to be
slightly higher for the seven MPNST cell lines as com-
pared to the DSSCTG values of a panel of 94 cell lines
from colon and ovarian cancer and leukemia
(Fig. 3B), and significantly higher in MPNST cells for
gemcitabine. Notably, in the extended drug panel con-
sisting of 527 compounds tested on the three MPNST
cell lines HS-PSS, HS-Sch-2, and YST-1 only, another
PLK1 inhibitor, GSK-461364, showed even higher
DSSCTG values for all three cell lines than BI2536 and
volasertib (Table S5), while the PLK1 inhibitor TAK-
960 did not inhibit these cells. High DSS values were
also observed for the kinase inhibitor rigosertib, which
is an inhibitor of both PLK1 and PI3K.
3.2. Cellular responses on specific compounds
The apoptotic response to specific compounds was
measured using a photometric caspase 3/7 assay in the
four cell lines S1507-2, S462, ST8814, and STS26T
after 72 h of drug exposure normalized to cells treated
with staurosporin as positive control. We found that
both PLK1 inhibitors, BI2536 and volasertib, induced
apoptosis in the TP53-mutant cell lines S1507-2 and
S462, as well as in the TP53 wild-type cells ST8814,
while the STS26T cell line, which harbors a homozy-
gous 10-bp deletion in exon 4 of TP53, had the lowest
level of apoptosis induced by PLK1 inhibition
(Fig. 3C). In the presence of gemcitabine, all the four
cell lines showed a moderate apoptotic response at 15–
30% under our assay conditions (Fig. 3C).
One of the MPNST cell lines, STS26T, had an onco-
genic V600E mutation in BRAF (Fig. 3C), which is a
known marker for benefit of BRAF inhibition in
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Fig. 1. Drug response heatmaps from CellTiter-Glo (CTG) viability assay for seven MPNST cell lines, two normal human Schwann cell (HSC)
cultures, and bone marrow (mean result from five healthy individuals). Drug responses for targeted drugs (excluding chemotherapeutic
drugs) with a drug sensitivity score (DSSCTG) of 10, or more, in at least one MPNST cell line (A), and chemotherapeutic and other targeted
drugs that have been used in clinical treatment of patients with MPNST (B). The same color coding and DSS gradient is used for both
heatmaps.
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Complete dataset:
299 compounds
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81 compounds
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4 MPNST cell lines
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527 compounds
5 Bone marrow aspirates
299 compounds
Fig. 2. Identification of candidate drugs for MPNST treatment. Filtering steps used to identify drugs with high specificity and selectivity
toward MPNST as compared to bone marrow and normal human Schwann cells (HSC) based on drug sensitivity scores from CellTiter-Glo
viability assay (DSSCTG).
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melanoma. We only detected a weak sensitivity against
the five tested BRAF inhibitors, RAF265, vemu-
rafenib, regorafenib, dabrafenib, and sorafenib in
STS26T, with similar results found for the BRAF wild-
type cell lines. Actually, the normal HSCs were moder-
ately more sensitive than all the MPNST cell lines.
3.3. Gene and protein expression of drug targets
in MPNST
The expression of drug targets in the MPNST cell lines
and HSC was examined by exon-level gene expression
arrays and protein expression arrays in vitro. On the
gene expression level, there was little variation in the
expression of PLK1 between MPNST cell lines and
HSC (Fig. S5A). On the protein level, however, we
found that the expression of PLK1 was higher in the
MPNST cell lines as compared to normal HSC
(Fig. 4A). Among all the 271 tested proteins on the
RPPA array, PLK1 ranked among the top 10 with
respect to difference between MPNST and normal cells
(Table S7), suggesting that PLK1 is an accessible tar-
get in MPNST cells. The increased expression of
PLK1 in MPNST as compared to HSC was not asso-
ciated with gain of gene copy number, as assessed in
four MPNST cell lines. Actually, two of the cell lines,
S1507-2 and ST8814, had genomic losses from a chro-
mosomal region covering PLK1 (16p12.2), and for
ST8814, this may partly explain the relatively low
PLK1 protein level as compared to the other MPNST
cell lines (Fig. 4B).
Gene expression data were also available for 30
MPNST patient samples and eight benign neurofibro-
mas (Kolberg et al., 2015), and in these patient sam-
ples, the gene expression of PLK1 was significantly
upregulated in malignant tumors as compared to
benign tumors (P = 0.004, two-sided independent sam-
ples t-test with equal variance; Fig. 4C, left panel).
Among the 30 MPNST samples, a high level of PLK1
expression was associated with large tumor size and
high tumor grade (Fig. 4C, right panel). Patients with
higher PLK1 expression also showed worse outcome in
univariate analysis, although slightly above the 5%
significance level (Fig. 4D). The mechanism of action
is more complex for gemcitabine, but one of its direct
targets is RRM1 where gemcitabine acts as a suicide
substrate (Kolberg et al., 2004; Pereira et al., 2004).
We did not observe any significant difference in
RRM1 or its activator and binding partner RRM2 in
the MPNST cell lines as compared to HSC1
(Fig. S5A); however, these genes were both signifi-
cantly upregulated in MPNST patient tumor samples
as compared to benign neurofibromas (Fig. 4E). The
level of RRM2 was positively correlated with tumor
grade and size, and strongly associated with poor
patient outcome (Fig. 4E,F). For RRM1, there was
































































Fig. 3. Independent validation and apoptosis assay of MPNST-specific drugs. Comparison of drug sensitivity scores from initial (blue bars,
including average data and standard deviation for the five bone marrow samples) CellTiter-Glo viability assay (DSSCTG), and two subsequent
validation rounds [manual (medium gray bars); custom plate (white bars)] (A). DSSCTG obtained for the three drugs BI2536 (dark blue),
volasertib (medium blue), and gemcitabine (light blue) from MPNST cell lines in comparison with a reference set of 94 cancer cell lines
(colon, ovarian, and leukemia); two-tailed P-values from independent samples t-test, assuming unequal variance (B). The maximum level of
apoptosis measured by a luminescence-based caspase-3/7 activation assay, induced by BI2536 (dark blue), volasertib (medium blue), and
gemcitabine (light blue), in comparison with staurosporin (100% apoptosis, pink) and 0.1% DMSO (0% apoptosis) (C). The mutation status
of TP53 and BRAF in each cell line is shown (het—heterozygous; hom—homozygous).
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Fig. 4. Expression of the drug targets PLK1, RRM1, and RRM2 in MPNST cell lines and prognostic relevance in patients with MPNST.
Normalized RPPA protein expression of PLK1 in MPNST cell lines (median = 0 across 271 cancer-relevant proteins) indicates an increased
expression of PLK1 in seven MPNST cell lines as compared to the mean of duplicate runs of normal Schwann cell HSC1 (A). Regions of
genomic gain (red) are not observed in the region on chromosome 16 harboring PLK1 (16p12.2) in the tested MPNST cell lines, while
regions of loss (blue) are observed in the two cell lines S1507-2 and ST8814 (B). Gene expression of PLK1 is significantly higher in MPNST
tumor samples as compared to benign neurofibromas (C, left panel), and high expression in MPNST is associated with high tumor grade
and large tumor size (C, right panel). MPNST patients with high expression of PLK1 in the tumor had worse outcome than patients with low
expression, although not significantly at a 5% level (the P-value and hazard ratio (HR) for PLK1 expression as a continuous variable in
univariate Cox regression analysis for five-year disease-specific survival are shown) (D). The gene expression of gemcitabine target RRM1
and its activator RRM2 is significantly higher in MPNST tumor samples as compared to benign neurofibromas (E, left panel), and high
expression of RRM2 in MPNST is associated with high tumor grade and large tumor size (E, right panel). MPNST patients with high
expression of RRM2 in the tumor had significantly worse outcome than patients with low expression (P-value and hazard ratio (HR) for gene
expression as a continuous variable in univariate Cox regression analysis for 5-year disease-specific survival are shown) (F).
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also an association with poor outcome, although not
statistically significant in our patient sample series
(Fig. S5E). There was no significant difference in gene
expression of the three genes in patient samples from
non-NF1- and NF1-associated MPNSTs (Fig. S5B–
D).
4. Discussion
There is a need for improved treatment options
against MPNST, and to this end, we have systemati-
cally tested a comprehensive library of approved and
investigational compounds to identify drug candidates
that show differential inhibition of MPNST cell
growth compared to normal Schwann cells and bone
marrow cells. This approach was chosen to identify
drugs with low neuro- and myelotoxicity, which are
common dose-limiting side effects in the clinical set-
ting. Due to the young age at onset and long life
expectancy after curative treatment, avoiding systemic
side effects is of particular importance for patients
with MPNST. The selection thresholds for the identifi-
cation of potential new drug candidates were chosen
to ensure robust selection of candidate drugs based
on true biological differences between MPNST cell
lines, normal nerve sheath cells, and bone marrow
cells. Other dose-limiting side effects associated with
the drugs, such as gastrointestinal, dermatological,
and liver toxicities, were not tractable in our preclini-
cal models.
Recently, several landmark studies have demon-
strated how cell lines recapitulate the major molecular
phenotypes of cancer and have substantiated their
value as preclinical model systems to assess a variety
of pharmacogenomic relationships with potential ther-
apeutic impact (Barretina et al., 2012; Garnett et al.,
2012; Greshock et al., 2010; Haverty et al., 2016).
Unfortunately, no MPNST cell lines were included in
these studies, highlighting the need for a large system-
atic screen of available and emerging drugs in a panel
of MPNST cell lines to select promising candidates for
clinical testing. In our study, we present drug response
as DSS values which are derived from the area under
the dose–response curves for each drug, and this mea-
sure has recently been demonstrated to provide better
agreement when comparing results from different labo-
ratories than the inflection points of the dose–response
curve (IC50) (Mpindi et al., 2016).
The most promising drug candidates identified here
include the PLK1 inhibitors volasertib and BI2536,
and the fluoronucleoside gemcitabine. PLK1 plays an
important role in progression of the cell cycle and is
known to be overexpressed in many different cancer
types, which makes this gene an interesting therapeutic
target (Abbou et al., 2016; Gjertsen and Schoffski,
2015; Gutteridge et al., 2016). In patient biopsies of
MPNST, we and others have shown expression
changes in various cell cycle-associated proteins (Age-
sen et al., 2005; Berner et al., 1999; Endo et al., 2011;
Kourea et al., 1999; Nielsen et al., 1999). Here, we
report that PLK1 is overexpressed in MPNST com-
pared to benign patient samples; in MPNST cell lines,
PLK1 protein expression is higher than in normal
HSC. However, the increased expression of PLK1 can-
not be explained by DNA copy number aberrations,
neither in patient samples (Brekke et al., 2010) nor in
the cell lines reported here. Furthermore, there was no
clear difference in mRNA levels between the mean of
the MPNST cells and HSC1 cells. This suggests that
the PLK1 is stabilized at the protein level, at least in
the MPNST cell lines. A possible mechanism for
PLK1 stabilization might be the deregulation of the
SCFbTrCP/proteasome degradation pathway, which has
recently been described as a degradation pathway for
PLK1 (Giraldez et al., 2017).
Ongoing efforts aim to develop PLK1 inhibitors
with improved pharmacokinetic and dynamic profiles,
and volasertib is currently the most clinically advanced
PLK1 inhibitor (Gjertsen and Schoffski, 2015). BI2536
was among the first PLK1 inhibitors to be tested in
the clinic, but the efficacy was limited, partly due to
the short terminal half-life. Nevertheless, the drug
seemed to be well tolerated (Schoffski et al., 2010).
The effect of the PLK1 inhibitor TAK-960 was
recently assessed in a panel of sarcoma cell lines,
including two MPNST cell lines (Nair and Schwartz,
2015). Nair and Schwartz found that all tested cell
lines were sensitive to TAK-960 at nanomolar concen-
trations. The authors also found that inhibition of
PLK1 in the TP53-mutant MPNST cell lines, both by
small compound inhibition and by siRNA-mediated
gene knockdown, led to the induction of polyploidy,
which was in contrast to TP53 wild-type or TP53/
sarcoma cell lines where PLK1 inhibition led to G2
arrest and apoptosis (Nair and Schwartz, 2015). In our
study, however, we also observed apoptosis in the two
TP53-mutant cell lines S1507-2 and S462, which carry
point mutations P152L and R110P, respectively
(Fig. 3C). Apparently, the TP53 status is not sufficient
to explain the relationship between PLK1 inhibition
and induction of apoptosis. The available data from
other cancer cell lines indicated that MPNST cells
have a uniquely high sensitivity toward gemcitabine
and PLK1 inhibitors (Fig. 3B), which suggests that the
biological processes inhibited by these drugs cannot be
easily compensated by other pathways in MPNST
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cells, at least not within the timeframe of the com-
pound screen. The high sensitivity toward PLK1 inhi-
bitors in MPNST as compared to other cancer cell
lines may at least in part be linked to the increased
RAS signaling due to the loss of tumor suppressor
NF1. This is supported by studies of colon cancer
models showing increased sensitivity toward PLK1
inhibition in KRAS-mutated cells (Luo et al., 2009;
Wang et al., 2016).
We have previously reported that enzymes in the
nucleotide metabolism, in particular thymidine meta-
bolism, are upregulated in MPNST (Kolberg et al.,
2015). Several drugs interfering with this pathway
were indicated as potential candidates in the drug
screen performed here, including the fluoronucleosides
gemcitabine and floxuridine, the thiopurines thiogua-
nine and mercaptopurine, as well as the folate antag-
onists methotrexate and pemetrexed. Of these, we
validated the effect of gemcitabine, an inhibitor of
RRM1 and de novo DNA synthesis (Kolberg et al.,
2004). Gemcitabine is already approved for many dif-
ferent cancer types, including sarcoma (Ducoulombier
et al., 2016). Resistance against gemcitabine may
partly be mediated by metabolic inactivation of gemc-
itabine catalyzed by cytidine deaminase (CDA) (Gil-
bert et al., 2006). However, we did not see any
differences in CDA expression levels in the MPNST
cells as compared to HSC.
The gene expression data from patients with
MPNST and benign tumors suggest that the drug tar-
gets PLK1 and RRM1, as well as the RRM1 activator
RRM2, are upregulated in malignant tumors and that
the level of aggressiveness, as indicated by patient sur-
vival, is directly associated with the gene expression
levels, especially for RRM2 (Fig. 4C–F). A continuous
supply of deoxyribonucleotides provided by the
RRM1/RRM2 complex is required in rapidly growing
and dividing cells, and PLK1 is needed to promote cell
cycle progression and to avoid apoptosis. Therefore,
inhibition of these factors might be especially effective
in the most aggressive tumors. In a clinical setting,
PLK1 and RRM2 expression may have both prognos-
tic and predictive values, as patients with high expres-
sion of these genes are most likely to experience
disease progression, and at the same time, those with
the highest levels are most likely to respond to PLK1
inhibitors and gemcitabine treatment. Interestingly, a
recent study in pancreatic cancer cells showed that
PLK1 inhibition enhances the effect of gemcitabine,
also in gemcitabine-resistant cells (Li et al., 2016). In
view of the current results, a therapeutic combination
strategy with gemcitabine and PLK1 inhibitors seems
rational also for patients with MPNST.
Novel drug targets for MPNST have also been sug-
gested by others based on preclinical findings (Semen-
ova et al., 2017; Teicher et al., 2015; Yamashita et al.,
2014). A recent drug screen of 63 sarcoma cell lines,
including the two MPNST cell lines MPNST and
ST8814, confirmed the heterogeneous responses among
different soft tissue cancers (Teicher et al., 2015).
None of the highlighted drugs in that study were
found to be targeting MPNST cells, with the exception
of a moderate inhibition by the PARP1 inhibitor tala-
zoparib, and weak effect of selected aurora kinases
(TAK-901, SCH-1473759, AS-703569, and ABT-348)
(Teicher et al., 2015). However, in the available raw
data, which were recorded after 96-h drug exposure,
both PLK1 inhibitors BI2536 and volasertib, as well
as gemcitabine, were among the top-ranked drugs with
respect to low IC50 values, which are in agreement
with our own data (Fig. S6).
In conclusion, we have identified two PLK1 inhibi-
tors, BI2536 and volasertib, and the DNA synthesis
inhibitor gemcitabine as highly effective against
MPNST cells, while being tolerable to normal HSC
cells and bone marrow cells, and we propose these
drugs as good candidates for future clinical testing,
alone or in combination. The expression levels of tar-
get genes for these treatments also carry prognostic
value, and we advocate for their potential as prognos-
tic and predictive factors for future clinical trials to be
further elucidated.
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